Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease

导出原文传递

翻译打印收藏纠错

作者： Erlinge,D. ^[1] ; James,S. ^[2] ; Duvvuru,S. ^[3] ; Jakubowski,J.A. ^[4] ; Wagner,H. ^[5] ; Varenhorst,C. ^[6] ; Tantry,U.S. ; Brown,P.B. ; Small,D. ; Moser,B.A. ; Sundseth,S.S. ; Walker,J.R. ; Winters,K.J. ; Gurbel,P.A.

作者单位： Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University ^[1] Sinai Center for Thrombosis Research, Baltimore, MD, United States ^[2] Daiichi Sankyo Pharma Development, Edison, NJ, United States ^[3] Cabernet Pharmaceuticals Durham, NC, United States ^[4] Department of Cardiology, Lund University, Lund, Sweden ^[5] Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, United States ^[6]

关键词 Clopidogrel Genotyping techniques Pharmacogenetics CYP2C19 polymorphisms Prasugrel

发布时间 2014-07-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交